CoChat

A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes

Khan, Safi U, Talluri, Swapna, Riaz, Haris, Rahman, Hammad, Nasir, Fahad, Bin Riaz, Irbaz, Sattur, Sudhakar, Ahmed, Haitham, Kaluski, Edo, Krasuski, Richard · 2018 · European Journal of Preventive Cardiology

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Abstract

Background: The comparative effects of statins, ezetimibe with or without statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed. Design: Bayesian network meta-analysis was conducted to compare treatment groups. Methods: Thirty-nine randomized controlled trials were selected using MEDLINE, EMBASE, and CENTRAL (inception – September 2017). Results: In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). PCSK9 inhibitors reduced the risk of major adverse cardiovascular events compared with ezetimibe + statin (odds ratio (OR): 0.72; 95% credible interval (CrI), 0.55–0.95; Grading of Recommendation Assessment, Development and Evaluation (GRADE) criteria: moderate), statin (OR: 0.78; 95% CrI: 0.62–0.97; GRADE: moderate) and placebo (OR: 0.63; 95% CrI: 0.49–0.79; GRADE: high). The PCSK9 inhibitors were consistently superior to groups for major adverse cardiovascular event reduction in secondary prevention trials (SUCRA, 95%). Statins had the highest probability of having lowest rates of all-cause mortality (SUCRA, 82%) and cardiovascular mortality (SUCRA, 84%). Compared with placebo, statins reduced the risk of all-cause mortality (OR: 0.88; 95% CrI: 0.83–0.94; GRADE: moderate) and cardiovascular mortality (OR: 0.84; 95% CrI: 0.77–0.90; GRADE: high). For cardiovascular mortality, PCSK9 inhibitors were ranked as the second best treatment (SUCRA, 78%) followed by ezetimibe + statin (SUCRA, 50%). Conclusion: PCSK9 inhibitors were ranked as the most effective treatment for reducing major adverse cardiovascular events, myocardial infarction and stroke, without having major safety concerns. Statins were ranked as the most effective therapy for reducing mortality.

Overview

Integrity signals

Registry

Crossref · 10.1177/2047487318766612

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Research works printed but not linked: 6

  1. Toth PP, 2017, J Am Heart Assoc, 6
  2. Kastelein JJ, 2015, Eur Heart J, 36, 2996
  3. Koren MJ, 2004, J Am Coll Cardiol, 44, 1772
  4. Stroes E, 2016, J Am Heart Assoc, 5
  5. Khan AR, 2017, Circ Cardiovasc Qual Outcomes, 10
  6. Schmidt AF, 2017, Cochrane Database Syst Rev, 4, Cd011748

Cited by

See all 61

Metadata

Authors
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R.
Affiliations
  • Guthrie Robert Packer Hospital (US)
  • Cleveland Clinic (US)
  • Mayo Clinic, Rochester, MN, USA
  • Duke University (US)
Corresponding author
Khan, Safi U
Venue
European Journal of Preventive Cardiology
Published
2018-03-23
Volume
25
Issue
8
Pages
844-853
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2789251847
Cited by
61
References
61
Citations by year
2026: 2 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 4 · 2020: 8 · 2019: 11 · 2018: 1
FWCI
1.33
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
PCSK9 inhibitors, statins, ezetimibe, major adverse cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, all-cause mortality, hypercholesterolemia, secondary prevention, lipid-lowering therapy, treatment ranking, SUCRA ranking, GRADE quality of evidence, cost-effectiveness, quality of life
MeSH terms
Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Anticholesteremic Agents, Bayes Theorem, Cardiovascular Diseases, Drug Therapy, Combination, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Serine Proteinase Inhibitors, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. https://app.cochat.ai/papers/10.1177/2047487318766612
The paper
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018). A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487318766612

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.